Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) is now available.
Shandong Boan Biotechnology Co., Ltd. has received approval from the U.S. FDA to initiate clinical trials for its novel ADC, BA1302, targeting CD228 for the treatment of solid tumors. This development marks a significant step in the company’s global clinical advancement, as BA1302 shows promising potential as a monotherapy and in combination with other treatments, offering new hope for cancer patients worldwide.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative antibody-drug conjugates (ADCs) for the treatment of various cancers. The company is engaged in in-depth research on targets, antibodies, and linker-payloads, with a strong emphasis on creating optimized ADC platforms.
Average Trading Volume: 15,117,230
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$7.82B
For detailed information about 6955 stock, go to TipRanks’ Stock Analysis page.